Patent applications published 30 June 2010
Selected patent applications from the weekly European Patents Bulletin
- Novel compsns and methods for cancer treatment
Boston Biomedical 2200431*
- Substituted pyrimidinyl-amines as protein kinase inhibitors
Scrips Research Institute 2200436*
- Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
Duquesne University of the Holy Ghost 2200437*
- Combination of pyremethanil and silver compounds
Janssen Pharmaceutica 2200438*
- HDAC inhibitors
Lixte Biotechnology 2200439*
- Antibacterial amide and sulphonamide substituted heterocyclic urea compounds
Crestone 2200440*
- Compsn and method for the prevention of oral disease
Micropure 2200441*
- Bacteriophage or lytic protein derived from the bacteriophage which effective for treatment of Staphylococcus aureus biofilm
Intron Biotechnology 2200442*
- Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
Cornell University 2200443*
- Resveratrol ferulate compounds, compsns containing the compounds, and methods of using the same
ELC Management 2200573*
- Novel use of Panduratin derivatives or extract of Kaempferia pandurate comprising the same
Newtree 2200574*
- Cosmetic agent containing purine and/or a purine derivative and hydrogen peroxide
Henkel 2200575*
- Novel use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same
Biocre; Newtree 2200576*
- Cytocompatible alginate gels
Abbott Cardiovascular Systems 2200578*
- Antiviral topical formulations in the form of a bio-adhesive gel
Fidia Farmaceutici 2200579*
- Method for the immobilisation of bioactive molecules within a polymeric substrate resistant to the stomach acids as oral drug delivery system
Smolko, Eduardo Esteban; Lombardo Eduardo Antonio; Lombardo, Fabio Martin; Lombardo, Jorge Héctor 2200580*
- Steroid containing ophthalmic drug delivery systems
Allergan 2200581*
- Use of carriers as preservatives and pharmaceutical compsn containing same
Galderma Research & Development 2200582*
- Stable formulations of amylin and its analogues
Novo Nordisk 2200583*
- Formulations containing cyclin-dependent kinase inhibiting compound and method of treating tumours use the same
Schering 2200584*
- Use of deuterium oxide for treating virus-based skin diseases
Firma D20 Bioscience Group 2200585*
- Improved liposomes and uses thereof
Synvolux 2200586*
- Dry powders of cellular material
President and Fellows of Harvard College 2200587*
- Compsns comprising lipophilic active compounds and method for their preparation
Solubest 2200588*
- Compsns and methods for treating post-operative pain using clonindine and bupivacaine
Medtronic; Warsaw Orthopaedic 2200589*
- Compsn and method of stabilised sensitised ingredient
Procter & Gamble 2200590*
- Controlled release pharmaceutical dosage forms of trimetazidine
Ranbaxy Laboratories 2200591*
- Adhering troches with topically active ingredients for treatment of throat, oesophagus and stomach
Orahealth 2200592*
- Abuse resistant drug formulation
CIMA labs 2200593*
- Oral dosage combination pharmaceutical packaging
MicroDose Therapeutx 2200594*
- Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
Janssen Pharmaceutica 2200595*
- Method of treating Gaucher disease
The Hospital for Sick Children; McMaster University 2200596*
- Method to ameliorate oxidative stress and improve working memory via pterostilbene adminstration
The United States of America, as represented by the Secretary of Agriculture 2200597*
- Interval therapy for the treatment of tinnitus
Merz Pharma 2200598*
- 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss
Merz Pharma 2200599*
- 1-amino-cyclohexane derivatives for the treatment of cochlear tinnitus
Merz Pharma 2200600*
- Blockers of serotonin and its receptors for the treatment of hepatitis
Universität Zurich Prorektorat Mnw 2200601*
- Controlled release tamsulosin hydrochloride tablets and a process of making them
Lek Pharmaceuticals 2200602*
- Osmolytes for the treatment of allergic or viral respiratory diseases
Bitop 2200603*
- Methods of increasing sarcosine levels for treating schizophrenia
BG Medicine 2200604*
- Method of stabilising quercetin
Quercegen Pharma 2200605*
- Process for the preparation of compounds useful as inhibitors of SGLT
Janssen Pharmaceutica; Mitsubishi Tanabe Pharma 2200606*
- Compounds that modulate intracellular calcium
Calcimedica 2200607*
- Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases
Gilead Sciences 2200608*
- Compounds for the treatment of metabolic disorders
Prosidion 2200609*
- Co-administration of pimavanserin with other agents
Acadia Pharmaceuticals 2200610*
- Compsns and methods for the treatment of progressive multifocal leukoencephalopathy (PML)
Biogen Idec 2200611*
- Inhibitors of janus kinases
Merck Sharp & Dohme 2200612*
- Phenazine derivatives and uses thereof
The Johns Hopkins University 2200613*
- Treatment of vasomotor symptoms
Boehringer Ingelheim International 2200614*
- A3 adenosine receptor antagonists
Gilead Palo Alto 2200615*
- Mipo inhibitors for the treatment of Huntington’s disease and multiple symptom atrophy
AstraZeneca 2200616*
- Improved brimonidine compsns for treating erythema
Galderma Laboratories 2200617*
- Soluble dosage forms containing cephem derivatives suitable for parenteral administration
AstraZeneca 2200618*
- Infectious disease testing of menstrual fluid, endometrial/menstrual cells, amniotic fluid, umbilical cord blood or other samples
Cryo-Cell International 2200620*
- Methods, pharmaceutical compsns and articles of manufacture for administering therapeutic cells to the animal central nervous system
Frey II, William; Danielyan, Lusine; Gleiter, Christoph 2200621*
